Table 1 Demographic and clinical characteristics of each group
Variable | Drug N (%) | Placebo N (%) | P value |
|---|---|---|---|
Menopausal statement | 0.735 | ||
Pre-menopause | 8 (44.4) | 7 (38.9) | |
Menopause | 10 (55.6) | 11 (61.1) | |
Stage of disease | 0.728 | ||
1 | 1 (5.6) | 1 (5.6) | |
2 | 10 (55.6) | 11 (61.1) | |
3 | 7 (38.9) | 6 (33.3) | |
Affected lymph nodes | 1 | ||
0 | 4 (22.2) | 4 (22.2) | |
≥1 | 14 (77.8) | 14 (77.8) | |
Tumor size (cm) | 0.566 | ||
< 2 | 5 (27.8) | 6 (33.3) | |
≥ 2–5 | 10 (55.6) | 11 (61.1) | |
≥ 5 | 3 (16.7) | 1 (5.6) | |
Hormone therapy | 0.682 | ||
Not received | 3 (16.7) | 3 (16.7) | |
Tamoxifen | 3 (16.7) | 2 (11.1) | |
Letrozol | 6 (33.3) | 5 (27.8) | |
Tamoxifen and letrozol | 0 (0) | 2 (11.1) | |
Tamoxifen and Decapeptyl | 6 (3.3) | 6 (33.3) | |
Frequency of Taxol/Taxotere injection | 1 | ||
4 | 17 (94.4) | 17 (94.4) | |
> 4 | 1 (5.6) | 1 (5.6) |